Pasithea Therapeutics Corp (KTTA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pasithea Therapeutics Corp stock (KTTA) is currently trading at $0.77. Pasithea Therapeutics Corp PS ratio (Price-to-Sales) is 42.15. Analyst consensus price target for KTTA is $3.00. WallStSmart rates KTTA as Sell.
- KTTA PE ratio analysis and historical PE chart
- KTTA PS ratio (Price-to-Sales) history and trend
- KTTA intrinsic value — DCF, Graham Number, EPV models
- KTTA stock price prediction 2025 2026 2027 2028 2029 2030
- KTTA fair value vs current price
- KTTA insider transactions and insider buying
- Is KTTA undervalued or overvalued?
- Pasithea Therapeutics Corp financial analysis — revenue, earnings, cash flow
- KTTA Piotroski F-Score and Altman Z-Score
- KTTA analyst price target and Smart Rating
Pasithea Therapeutics Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Pasithea Therapeutics Corp (KTTA) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Pasithea Therapeutics Corp (KTTA) Key Strengths (2)
Revenue surging 1498.00% year-over-year
Trading at 1.51x book value, attractively priced
Supporting Valuation Data
Pasithea Therapeutics Corp (KTTA) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 42.1x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Pasithea Therapeutics Corp (KTTA) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.51) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 1498.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (42.15) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -89.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -89.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1498.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KTTA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KTTA's Price-to-Sales ratio of 42.15x sits near its historical average of 42.15x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 42.15x set in Mar 2026, and 0% above its historical low of 42.15x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Pasithea Therapeutics Corp (KTTA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Pasithea Therapeutics Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 486,560 with 1498% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 1498% YoY, reaching 486,560. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 279% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Pasithea Therapeutics Corp maintain 1498%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Pasithea Therapeutics Corp.
Bottom Line
Pasithea Therapeutics Corp is a high-conviction growth story with revenue accelerating at 1498% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Pasithea Therapeutics Corp(KTTA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.